GLPG 3312
Alternative Names: GLPG-3312Latest Information Update: 28 Feb 2022
At a glance
- Originator Galapagos NV
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Salt-inducible kinase 3 inhibitors; Salt-inducible kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Netherlands (PO, Tablet)
- 10 Mar 2020 Galapagos NV completes a phase I clinical trials in Inflammation (In volunteers) in Netherlands (PO, Tablet) (NCT03800472)
- 24 Sep 2019 Galapagos plans a phase II trial for Ulcerative colitis in H1 2020